Tenderwize
Wróć do wyszukiwania

Open-house rebate agreements for Xipamid

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Jan 03, 2028 · 493 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Xipamid, ATC C03BA10

58/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

58 / 100

Złożoność

42 / 100

Czynniki ryzyka

The notice says the model is open-house and not subject to ordinary procurement selection logic, which may affect legal...

Documents must be submitted through the DTVP communication area, not the offer area; paper originals must be in duplica...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Feb 2028
  • Non-exclusive pharmaceutical rebate agreements for the active substance Xipamid (ATC C03BA10).
  • Open-house model with identical, pre-set contract terms and no individual negotiation.
Pokaż pełne podsumowanie

This is an open-house pharmaceutical supply arrangement for Xipamid (ATC C03BA10) led by AOK Bayern. It is not a competitive award procedure in the usual sense: all interested pharmaceutical companies that meet the stated eligibility condition can join on identical, non-negotiable terms. The contract period runs from 01.03.2026 to 29.02.2028, with contract entry possible until 03.01.2028. Submission is via DTVP electronic portal with a qualified electronic signature or by signed paper originals in duplicate; German language is required, and non-German documents must be submitted with German translation.

Ryzyka

The notice says the model is open-house and not subject to ordinary procurement selection logic, which may affect legal...

Documents must be submitted through the DTVP communication area, not the offer area; paper originals must be in duplica...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • The contract and annex 'Determination of the contract products' must be completed and signed.

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • A signed declaration of reliability must be submitted.

Zamawiający

Lokalizacja

München, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE811695320

Działalność

Health

Części (1)

LOT-0001

Open-house rebate agreements for Xipamid

Open-house supply arrangement for pharmaceutical rebate agreements concerning Xipamid (ATC C03BA10). The lot is described as a non-exclusive, identical, non-negotiable contract model for all eligible pharmaceutical companies. Performance is in Germany, Bavaria (DE212).

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

DE212, Germany

Czas trwania

Feb 2026 - Feb 2028

Kategoria

Pharmaceutical products

Termin

Deadline Jan 03, 2028

Szczegóły zamówienia

Data publikacji
13 Jan 2026
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
23964-2026

Dokumenty (2)

Dokument zamówienia 1Portal składania ofert 1

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30